🚀 Exciting News from 3B Future Health Fund! 🚀 We're thrilled to share the incredible progress of their portfolio company AnaCardio in the pursuit of innovative solutions for heart failure patients.
👉 For early-stage heart failure patients, GLP1 agonists have shown promising results. However, for severe cases, assist devices and heart transplants may be the only options.
🌟 Under the scientific leadership of the renowned cardiologist Lars Lund and CEO Patrik Strömberg, AnaCardio is pushing boundaries in the field.
💡 Did you know? 3B Future Health Fund II, backs US and European-based private early-stage, innovative companies in areas of high unmet patient needs. Their focus extends to start-up companies based in Europe, the US, and +D4Israel, with a specific investment focus on Oncology and Rare Diseases.
3B Future Health Fund I & II, Riccardo Braglia, Karolinska Development, Industrifonden, Flerie Mark Quick, Fredrik Lehmann, Per Aniansson, Karolinska Institutet, Helsinn Group, and BEV Advisory.
Together, we're making strides in advancing healthcare and transforming the landscape of heart disease treatment.